Robert H. Brown
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients.
Journal: International journal of cancer
Published: June 26, 2025
G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cells.
Journal: Genome biology
Published: November 08, 2024
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
Journal: Journal for immunotherapy of cancer
Published: March 15, 2022
Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?
Journal: Cancers
Published: February 14, 2022
Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
Journal: Clinical epigenetics
Published: March 17, 2021
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
Journal: Journal for immunotherapy of cancer
Published: November 18, 2020
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: October 08, 2020
Glycosylated Nanoparticles Derived from RAFT Polymerization for Effective Drug Delivery to Macrophages.
Journal: ACS applied bio materials
Published: September 21, 2020
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Journal: EMBO molecular medicine
Published: September 02, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 11, 2020
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.
Journal: Cell reports
Published: July 24, 2019
Last Updated: 09/26/2026